Massive mpox vaccine trial launches in DRC: could it stop the outbreak?

NCT ID NCT07093489

Not yet recruiting ⭐️ VACCINE ⭐️ Sponsor: International Vaccine Institute Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This large study will test the LC16m8 mpox vaccine in nearly 12,000 people aged one year and older in the Democratic Republic of Congo. Researchers want to see if the vaccine can prevent mpox disease and monitor its safety. Participants will receive the vaccine as part of the government's rollout, and the study will compare infection rates between vaccinated and unvaccinated groups.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: LC16m8 mpox vaccine
What this could lead to: If successful, this could provide a safe and effective vaccine to protect against mpox in both children and adults.
What could go wrong: This is a real-world study, not a controlled lab trial, so results may be less clear. The vaccine may not reach the hoped-for 70% protection, and safety in young children or pregnant women is not yet known.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MPOX are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

monkeypox prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MPOX MPOX (MONKEYPOX)

Contacts and locations

Locations

The Institut National de la Recherche Biomédicale (INRB)

Kinshasa, Democratic Republic of the Congo

More trials for these conditions

Other studies related to the condition(s) this trial covers.